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Abstract:  
Introduction: The cardiac dysfunction associated with anthracycline-based chemotherapy 
cancer treatment can exist sub-clinically for decades before overt presentation. Stress 
echocardiography, the measurement of left ventricular (LV) deformation and arterial 
haemodynamic evaluation have separately been used to identify sub-clinical cardiovascular 
(CV) dysfunction in several patient groups including those with hypertension and diabetes. 
The purpose of the present cross-sectional study was to determine whether the combination 
of these techniques could be used to improve the characterisation of sub-clinical CV 
dysfunction in long-term cancer survivors previously treated with anthracyclines.  
 
Materials and methods: Thirteen long-term cancer survivors (36±10 years) with prior 
anthracycline exposure (11±8 years post-treatment) and 13 age-matched controls were 
recruited. Left ventricular structure, function and deformation were assessed using 
echocardiography. Augmentation index was used to quantify arterial haemodynamic load and 
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was measured using applanation tonometry. Measurements were taken at rest and during two 
stages of low-intensity incremental cycling.  
Results: At rest, both groups had comparable global LV systolic, diastolic and arterial 
function (all P>0.05), however longitudinal deformation was significantly lower in cancer 
survivors (-18±2 v -20±2, P<0.05). During exercise this difference between groups persisted 
and further differences were uncovered with significantly lower apical circumferential 
deformation in the cancer survivors (-24±5 v -29±5, -29±5 v 35±8 for first and second stage 
of exercise respectively, both P<0.05).  
Conclusion: In contrast to resting echocardiography the measurement of LV deformation at 
rest and during exercise provides a more comprehensive characterisation of sub-clinical LV 
dysfunction. Larger studies are required to determine the clinical relevance of these 
preliminary findings. 
 
Key Words: Anthracyclines; exercise echocardiography; cardiac deformation; arterial 
haemodynamics 
 
Introduction: Despite the survival benefits of anthracycline-based chemotherapy in the 
treatment of cancer, these drugs are known to have a dose-dependent toxic effect on the heart 
[1]. Indeed, cancer survivors previously exposed to anthracyclines are at greater risk of 
developing cardiovascular (CV) disease than from recurrent cancer [2]. Anthracycline CV 
toxicity is progressive in nature and may persist sub-clinically for many years prior to the 
presentation of overt dysfunction [1]. Recent reviews examining cancer therapeutics-related 
cardiac dysfunction (CTRCD) have suggested that stress (both dobutamine and exercise) 
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echocardiography may be useful in the characterisation of sub-clinical LV dysfunction [3,4]. 
Latent LV dysfunction, otherwise disguised at rest, has been successfully uncovered during 
exercise in other patient groups (e.g. hypertension [5] and diabetes [6]). However, stress 
echocardiographic studies in the oncology setting have provided contradictory and 
inconclusive findings [3,7,8,9,10]. This lack of clarity may be explained by the use of global 
measures of LV function such as the E/A ratio [7], fractional shortening [8] or cardiac index 
[10] which may be insensitive to sub-clinical dysfunction. More recently, the measurement of 
LV myocardial deformation has shown potential in the detection of sub-clinical changes to 
LV function in cancer patients and also in the prediction of CTRCD [3,11]. Whilst promising, 
these studies were carried out at rest and did not assess arterial function, which is integral to 
the CV response to exercise and is also susceptible to anthracycline toxicity [12]. It is 
possible that the combination of stress echocardiography including myocardial deformation 
with sensitive markers of arterial function may help thoroughly characterise sub-clinical CV 
dysfunction in long-term cancer survivors. Therefore, the purpose of this study was to test the 
hypothesis that the concurrent assessment of cardiac deformation and arterial function during 
exercise would improve the characterisation of sub-clinical CV dysfunction in asymptomatic 
cancer survivors with prior anthracycline exposure compared to assessments taken at rest.  
 
Methods and materials: 
Study population: Thirteen asymptomatic cancer survivors (age 36 ±10 years, 10 male, 3 
female, with clinically recorded EF >50%) who had previously undergone anthracycline-
based chemotherapy and 13 age- and gender-matched healthy participants were recruited 
between January 2012 and August 2014 for this cross-sectional study (Table 1). The control 
participants for the study were recruited from the University teaching and post-graduate 
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population. Cancer diagnoses and patient treatment details are presented in Table 2. Prior to 
enrolment in the study, a resting electrocardiogram (ECG) and echocardiogram was obtained 
from all cancer survivors and assessed by the study cardiologist. Exclusion criteria were: 
overt cardiac pathology evident on echocardiogram or ECG, atrial fibrillation, use of cardiac 
medications, pregnancy, uncontrolled hypertension, severe diabetic neuropathy and/or 
retinopathy, renal failure and any orthopaedic conditions that would prohibit exercise. The 
study conformed to the principles outlined in the Declaration of Helsinki. Informed consent 
was provided by all participants and the study was approved by the South East Wales 
Research Ethics Committee.   
  
Experimental protocol: Participants attended the laboratory at Cardiff Metropolitan 
University on 3 occasions separated by at least 24-hours. Anthropometric measurements and 
a sub-maximal exercise test conducted on an upright cycle ergometer (Corival, Lode BV 
Medical Technology, Groningen, Netherlands) were completed in visits 1 and 2 respectively. 
The sub-maximal exercise test employed a ramp protocol and was stopped once participants 
had exceeded a respiratory exchange ratio of 1.0 [13]. Post-hoc the V-slope method [14] was 
applied to the sub-maximal gas exchange data (Oxycon Pro, Erich Jaeger GmbH, Hoechberg, 
Germany) to estimate the power output (w) associated with the individual anaerobic threshold 
(AT). It is acknowledged that AT determined from sub-maximal exercise test data will not be 
comparable to that obtained from a maximal test. However, the purpose of the present 
exercise test was to standardise the sub-maximal exercise intensity during the third laboratory 
visit. The exercise protocol in visit 3 involved 2 stages of incremental exercise on a supine 
cycle ergometer (Lode, Angio 2003, Groningen, Netherlands). The exercise intensities for 
each participant were determined by firstly correcting the upright power output for the supine 
position by deducting 20% [15], and then calculating 25% (exercise stage 1; Ex1) and 50% 
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(exercise stage 2; Ex2) of the corrected AT power. As the exercise protocol involved supine 
cycling sagitally rotated 45°, participants were familiarised with the ergometer during visit 1 
and 2. In visit 3, following 10-minutes of rest in the rotated supine position, LV and vascular 
function were simultaneously investigated using echocardiography and applanation 
tonometry respectively. Measurements were taken at rest and during Ex1 and Ex2. Each stage 
of the protocol lasted approximately 10-minutes with data collected during the last 6-minutes. 
Brachial blood pressure was measured manually at rest and during exercise (Spirit 
sphygmomanometer aneroid, CK-111, Taipei, Taiwan) and heart rate (HR) was recorded 
continuously via the ECG attached to the echocardiograph.  
 
Echocardiography: Echocardiographic images were collected and stored using a 
commercially available ultrasound machine (Vivid q, GE Medical Systems, Israel) equipped 
with a 1.5- to 4-MHz phased array sector transducer (M4S-RS). Images were acquired 
according to published guidelines [16,17] and were analysed using manufacturer-specific 
software (EchoPAC, GE Medical, Horten, Norway, version 112). Echocardiographic data 
were averaged over 3 cardiac cycles and images were analysed with the investigator blinded 
to the participant’s status.  
 
Left ventricular structure and global function: Left ventricular internal diameters and wall 
thicknesses were measured using 2-dimensional guided M-mode echocardiography. Left 
ventricular mass was determined according to the Devereux formula and indexed to body 
surface area [16]. Early (E) and late (A) peak diastolic filling velocities as well as the E/A 
ratio were determined from the trans-mitral Doppler trace. Peak myocardial tissue velocities 
during systole (s’), early diastole (e’) and late diastole (a’) were measured from the pulsed-
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wave Doppler trace of the septal mitral annulus. Left ventricular volumes including end-
systolic volume (ESV), end-diastolic volume (EDV) and stroke volume (SV) were calculated 
using the modified biplane Simpson’s method [16]. Cardiac output (CO) was calculated as 
the product of HR and SV. Ejection fraction (EF) was derived from the following equation: 
[(SV/EDV)*100].  
 
Left ventricular deformation: Left ventricular deformation was quantified by measuring 
LV strain using speckle tracking echocardiography as described previously [18]. Briefly, 4-
chamber long-axis (longitudinal strain) and basal and apical short-axis (circumferential 
strain) LV video loops were recorded and the endocardial border manually traced using 
specialised software (EchoPAC, GE Medical, Horten, Norway, version 112). Following 
initial processing the raw strain data were exported to custom software (2D strain analysis 
tool, version 1.0β14, Stuttgart, Germany) for further analysis resulting in the generation of 
peak longitudinal systolic strain and peak basal and apical circumferential systolic strain data. 
Arterial function: Pulse wave velocity (PWV) and augmentation index (AIx) were 
employed as markers of arterial function in this study and were measured using applanation 
tonometry. Carotid-femoral pulse wave velocity (PWV), the current non-invasive gold-
standard technique for the assessment of aortic stiffness, was measured at rest while 
augmentation index (AIx), a marker of arterial haemodynamic load, was evaluated at rest and 
during exercise [19]. Duplicate carotid-femoral PWV measurements were obtained using the 
“foot-to-foot” methodology described in detail previously [19]. The measurement of AIx 
involved the collection of radial pressure waveforms using a high-fidelity micromanometer 
(SPC-301; Millar Instruments, Texas, Houston), which were then transformed into central 
aortic waveforms using a generalised transfer function (GTF) (SphygmoCor7.01; AtCor 
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Medical, Sydney, Australia). From this waveform AIx was automatically derived by the 
SphygmoCor software [20]. The GTF has been validated both at rest [21] and during exercise 
[22]. Augmentation index data are reported as absolute values and, as this variable varies 
inversely with heart rate, relative to a heart rate of 75 bpm (AIx@75) [22].  
 
Statistical analysis: All data are presented as mean ± SD unless otherwise stated. Differences 
in resting haemodynamics and global CV structure and function between the cancer survivors 
and controls were explored using independent-samples t-tests. Differences in LV strain and 
AIx between groups at rest and during exercise were analysed using independent samples t-
tests with a Holm-Bonferroni correction applied for multiple comparisons. Statistical 
significance was set a priori at <0.05. Intra-observer reliability for selected 
echocardiographic variables at rest and during exercise was determined using intraclass 
correlation coefficients (ICC) with 95% confidence intervals in a separate test-retest study 
(n=10). Both at rest and during exercise, ICC for longitudinal and basal and apical 
circumferential strain varied between 0.91 and 0.99 (all P<0.0001).   
  
Results: Participant characteristics are reported in Table 1. The cancer survivor group was 
similar to the control group in age, sex, height, body mass and body surface area. None of the 
participants were taking any medications and all were free from co-morbidities. All of the 
cancer survivors successfully completed the two stages of exercise. The cancer survivors and 
control participants showed a similar oxygen uptake and power output during the sub-
maximal exercise test. Resting CV structure and function variables are presented in Table 3 
whilst exercise haemodynamic and LV and arterial function data are reported in Table 4.   
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Cardiovascular structure and function at rest: Resting LV wall thicknesses, cavity 
dimensions, volumes, HR and blood pressure were similar between cancer survivors and 
controls however cancer survivors had a significantly smaller LV mass than controls. Despite 
this difference, the cancer survivors were still well within normal reference ranges [16]. 
Global resting LV systolic (EF, SV, CO) and diastolic (E/A ratio) function were not different 
between groups. Measures of arterial function (PWV and AIx) were also similar in both 
groups at rest. Circumferential strain and a’ were not significantly different between groups at 
rest, in contrast, the cancer survivors had a lower resting longitudinal strain (Figure 1) and 
slower s’ and e’ compared to controls. 
  
Cardiovascular function during exercise: During exercise, blood pressures, HR, EF and CO 
were comparable between the cancer survivors and controls. Longitudinal strain and s’ 
remained significantly lower in the cancer survivors compared to controls during exercise. 
Despite similar resting basal and apical circumferential strain between the two groups, on 
exercise these variables were significantly lower in the cancer survivors during Ex1 (basal 
and apical circumferential strain) and Ex2 (apical circumferential strain). Although 
significantly lower at rest, e’ was similar in both groups throughout the exercise protocol. In 
contrast, a’ which was comparable at rest was significantly lower in the cancer survivors 
during Ex1. Cancer survivors had consistently higher AIx compared to controls during 
exercise but the difference did not reach statistical significance.  
 
Discussion: This study examined whether the concurrent assessment of cardiac deformation 
and arterial function during exercise would improve the characterisation of sub-clinical CV 
dysfunction in asymptomatic cancer survivors with prior anthracycline exposure compared to 
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assessments taken at rest. We found that despite having preserved global LV function (EF) at 
rest, cancer survivors have reduced resting LV long-axis function (lower longitudinal strain 
and slower s’ and e’). In addition, as hypothesised, further differences were uncovered during 
exercise with cancer survivors having reduced short-axis function (decreased circumferential 
strain) and slower late diastolic myocardial velocities (a’). However, no differences in arterial 
function were identified between the groups either at rest or during exercise. The findings 
from this study suggest that the assessment of cardiac deformation during exercise may 
provide a more comprehensive characterisation of sub-clinical LV dysfunction in cancer 
survivors previously exposed to anthracyclines than resting measures alone.  
 
Detection of sub-clinical cardiovascular dysfunction at rest 
The use of myocardial deformation indices in the detection [23,24] and prediction 
[11] of sub-clinical LV dysfunction in cancer patients undergoing anthracycline-based 
chemotherapy is well established. In contrast, there are only a limited number of research 
studies investigating the role of these indices in the early identification of sub-clinical 
changes to LV function in long-term cancer survivors. The present cohort of asymptomatic 
cancer survivors had preserved global LV function (EF) 10+ years post-treatment but reduced 
longitudinal deformation and slower systolic (s’) and early diastolic (e’) myocardial 
velocities at rest. These findings are consistent with previous studies involving long-term 
cancer survivors [25,26]. Sub-endocardial myofibers play a key role in LV long-axis function 
[27] and are particularly susceptible to a loss of functional myocytes, a common finding in 
biopsies taken from patients with prior anthracycline exposure [28]. Accordingly, endocardial 
fibre impairment may explain the reduced LV long-axis function observed at rest in the 
present cohort of cancer survivors.  
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The toxic effects of anthracyclines are not confined to the heart but also damage the 
arterial system causing irregular vascular tone, impaired nitric oxide production and the 
induction of endothelial apoptosis [29].  Previously, it has been shown that aortic wall 
stiffness is increased 4 months after chemotherapy in breast cancer, leukaemia and lymphoma 
patients [30]. In contrast to the previously observed short-term effects of anthracyclines, 
neither aortic stiffness nor arterial haemodynamic load in the present investigation were 
chronically increased in cancer survivors several years after the cessation of treatment. 
Earlier studies evaluating aortic stiffness in long-term cancer survivors have also found either 
a partial reversal 14 months post-treatment [31] or no differences between controls and 
cancer survivors 10+ years after treatment [32]. Whilst this may point to a recovery of the 
vasculature from prior anthracycline exposure, it is also possible that sub-clinical dysfunction 
is not evident at rest in young otherwise healthy cancer survivors.  
 
Unmasking latent sub-clinical cardiovascular dysfunction during exercise 
Blood supply to working muscles during exercise is enhanced via local processes such 
as decreased vasomotor tone and increased nitric oxide production [33], changes which also 
lead to reduced arterial haemodynamic load (AIx) [34]. As anthracycline exposure impairs 
these processes, it was hypothesised that exercise would provoke the appearance of latent 
differences in AIx between cancer survivors and controls. Yet there were no statistically 
significant differences in AIx between the groups during exercise suggesting no impairment 
of the vasculature of long-term cancer survivors at sub-maximal exercise intensities. Whether 
higher intensities are required to uncover differences in AIx in such an asymptomatic group 
of cancer survivors requires further investigation.  
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Conversely, the exercise stimulus was effective in unmasking additional differences 
in LV systolic (reduced circumferential strain) and diastolic (slower a’) function that were not 
apparent at rest. Moreover, longitudinal deformation remained lower in the cancer survivors 
throughout the exercise protocol. Tan and colleagues reported similar findings i.e. lower 
longitudinal function at rest and reduced short axis function only on exercise in older (~71 
years) hypertensive patients with NYHA Stage II and III heart failure [5]. Reduced 
circumferential deformation tends to occur in the more advanced stages of heart failure 
(NYHA Stage III and IV) while longitudinal deformation is reduced in the earlier stages 
(Stage I) of the condition [35]. In line with this pathophysiological progression, it appears 
that the current low-intensity exercise stimulus precipitated a degree of impaired LV short 
axis function in the cancer survivors more commonly associated with advanced cardiac 
damage. The timely identification of such damage may allow for improved risk stratification 
of cancer survivors and earlier intervention in those at most risk. However, longitudinal 
studies are firstly required to ascertain the association if any between reduced LV short axis 
function on exercise and the development of overt CV disease in this patient group.   
While the assessment of cardiac deformation during exercise appears to improve the 
characterisation of sub-clinical LV dysfunction in asymptomatic cancer survivors the clinical 
utility of such an approach is uncertain. Exercise echocardiography is an extremely 
challenging skill and this reduces the likelihood of it being rapidly adopted into clinical 
practice. Furthermore our data suggests that while providing more detail, CV evaluation 
during exercise did not distinguish sub-clinical CV dysfunction beyond that already 
determined by the resting assessment of LV longitudinal deformation. Larger studies are 
required to confirm our preliminary findings and to ascertain the added benefit of exercise 
echocardiography in the detection of sub-clinical CV dysfunction.    
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Limitations: There were several limitations to the present study including the small sample 
size and the cross-sectional design, which limits the conclusions that can be drawn from the 
current findings i.e. the effect of different treatment regimens on the outcome variables. 
Whilst the identification of sub-clinical LV dysfunction in cancer survivors contributes to the 
understanding of the pathological process underpinning CTRCD it has not yet been 
confirmed if these sub-clinical findings are associated with the development of overt clinical 
CV disease. Owing to ethical restrictions peak O2 was not measured in the present 
investigation. Consequently despite having similar sub-maximal O2, cancer survivors may 
have had lower peak O2 values, which in turn may have affected the interpretation of the 
data.  
 
Conclusion: The assessment of cardiac deformation during exercise appears to improve the 
characterisation of sub-clinical LV dysfunction in asymptomatic cancer survivors previously 
exposed to anthracyclines beyond that achieved with simple resting measures. However for 
the purpose of detecting sub-clinical LV dysfunction, the measurement of myocardial 
deformation at rest may be sufficient.  
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Figure legend: 
 
Figure 1: Differences in peak left ventricular strain between control and anthracycline groups at 
rest and during exercise (mean ±SD). The anthracycline group had significantly lower (less 
negative) longitudinal strain at rest and during Ex1 and Ex2 compared to controls (top). Despite 
comparable apical (middle) and basal (bottom) circumferential strain at rest the anthracycline group 
had significantly lower values (less negative) in these parameters during exercise. Ex1: exercise stage 
1; Ex2: exercise stage 2; *P<0.05; †P<0.01. 
 
Table 1: Demographics of study population (mean ±SD). 
Variable ANT (n=13) Control (n=13) P value 
Age (years) 36 ±10 35 ±12 0.742 
Gender (M/F) 10/3 10/3 ---- 
Height (cm) 174 ±9 175 ±11 0.906 
Body mass (kg) 80 ±13 79 ±15 0.868 
Body surface area (m-2) 1.9 ±0.2 1.9 ±0.2 0.940 
Co-morbidities None None ---- 
Medication None None ---- 
O2 at AT (ml·min-1·kg-1)* 18 ±4 19 ±4 0.369 
Workload at AT (W)* 95 ±30 110 ±38 0.294 
ANT: anthracycline; M: male; F: female; O2: oxygen uptake; AT: anaerobic threshold; *: AT 
determined using V Slope method applied to sub-maximal gas exchange data. 
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Table 2: Cancer diagnoses and treatment details (mean ±SD, % or range; n=13). 
Variable   
Cancer type  Hodgkin’s lymphoma 3 (23%) 
Non-Hodgkin’s lymphoma 6 (46%) 
Ewing’s sarcoma 1 (8%) 
Acute lymphoblastic leukaemia 3 (23%) 
Years since therapy 11 ±8 (range: 2-33) 
Age at cancer (years) 25 ±13 (range: 4-47) 
ANT type Doxorubicin 13 (100%) 
ANT cumulative dose (mg·m-2) 317 ±106 (range: 150-450) 
Radiotherapy Yes/No 5 (38%)/8 (62%) 
Radiotherapy location Abdomen 1 (8%) 
 
Mediastinum  2 (15%) 
 
Brain and spinal cord 1 (8%) 
 
Neck 1 (8%) 
ANT: anthracycline.  
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Table 3: Global cardiovascular structure and function at rest (mean ±SD). 
Variable ANT (n=13) Control (n=13) P value 
LV structure    
LVPWs (cm) 1.4 ±0.3 1.5 ±0.3 0.164 
LVIDs (cm) 3.3 ±0.4 3.4 ±0.4 0.562 
IVSs (cm) 1.4 ±0.2 1.5 ±0.3 0.453 
LVPWd (cm) 0.9 ±0.1 1.0 ±0.2 0.081 
LVIDd (cm) 4.7 ±0.4 4.9 ±0.5 0.295 
IVSd (cm) 1.0 ±0.2 1.1 ±0.2 0.106 
LV mass (g) 153 ±45 194 ±55 0.049 
LV mass index (g·m-2) 78 ±18 99 ±20 0.010 
LV volumes    
End-systolic volume (ml) 47 ±12 45 ±12 0.702 
End-diastolic volume (ml) 101 ±19 102 ±23 0.886 
Global LV systolic function    
Ejection fraction (%) 54 ±5 56 ±4 0.269 
Global LV diastolic function    
Trans-mitral E vel. (m·s-1) 0.7 ±0.1 0.7 ±0.2 0.682 
Trans-mitral A vel. (m·s-1) 0.4 ±0.1 0.3 ±0.1 0.361 
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E/A ratio 2.06 ±0.63 2.26 ±1.27 0.624 
Aortic stiffness    
C-F pulse wave velocity (m·s-1) 6.1 ±1.0 6.6 ±1.6 0.385 
ANT: anthracycline; LV: left ventricle; LVPW: left ventricular posterior wall; LVID: left ventricular 
internal diameter; IVS: inter-ventricular septum; s: systole; d: diastole; E: early diastolic; A: late 
diastolic; vel: velocity; C-F: carotid-femoral. 
Table 4: Haemodynamics and global left ventricular and arterial function at rest and during 
exercise (mean ±SD).  
                     Exercise Intensity 
 Rest Ex1 Ex2 
Haemodynamics 
Systolic blood pressure (mmHg) 
ANT 113 ±13 124 ±14 132 ±15 
Control 115 ±19 126 ±17 135 ±21 
Diastolic blood pressure (mmHg)  
ANT 68 ±9 78 ±8 79 ±5 
Control 68 ±11 74 ±10 77 ±11 
Heart rate (bpm)   
ANT 58 ±5 84 ±7 95 ±9 
Control 53 ±8 76 ±9 85 ±12 
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Global LV function   
Ejection fraction (%)    
ANT 54 ±6 59 ±5 59 ±5 
Control 56 ±4 60 ±4 64 ±4 
Cardiac output (L·min-1)   
ANT 3.6 ±1.1 5.8 ±1.2 6.7 ±1.7 
Control 4.0 ±1.0 6.2 ±1.6 7.4 ±2.0 
s’ (m·s-1)    
ANT 0.07 ±0.01† 0.08 ±0.01† 0.10 ±0.02† 
Control 0.09 ±0.01 0.10 ±0.01 0.12 ±0.01 
 
 e’ (m·s-1) 
   
ANT 0.09 ±0.02† 0.11 ±0.02 0.12 ±0.03 
Control 0.12 ±0.03 0.13 ±0.03 0.14 ±0.03 
a’ (m·s-1)    
ANT 0.07 ±0.02 0.09 ±0.02† 0.10 ±0.03 
Control 0.09 ±0.02 0.12 ±0.02 0.13 ±0.03 
Arterial Function     
Augmentation index (%)    
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ANT 20 ±15 13 ±14 7 ±14 
Control 11 ±12 8 ±10 1 ±8 
AIx@75 (%)     
ANT 12 ±14 18 ±14 17 ±13 
Control 1 ±12 9 ±9 6 ±10 
ANT: anthracycline; Ex1: exercise stage 1; Ex2: exercise stage 2; LV: left ventricular; s’: systolic 
myocardial velocity; e’: early diastolic myocardial velocity; a’: late diastolic myocardial velocity; 
AIx@75: augmentation index normalised to heart rate 75 bpm; *P<0.05; †P<0.01. 
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Figure 1: Differences in peak left ventricular strain between control and anthracycline groups at 
rest and during exercise (mean ±SD). 
P=0.05 
